AngioSoma, Inc.
Investor Presentation

September 2016

AngioSoma, Inc.
Corporate Overview

AngioSoma, Inc. is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ("PAD").

Our lead product candidate **Liprostin™** for the treatment of PAD has completed all of its preliminary U.S. Food and Drug Administration ("FDA") required Phase I and Phase II clinical trials successfully and is entering into Phase III, the final phase prior to approval. We are in discussions with several contract research organizations ("CRO") for completion of our FDA protocol for Phase III and submission of our new drug application ("NDA") for marketing in the US and its territories.

We have a robust pipeline of products from 20+ years of research and development, with expired patent technology, existing patents, provisional patents, formulations, and trademarks from previously successful products.

AngioSoma, Inc.
Business Plan

AngioSoma, Inc. treats each product in its pipeline as a separate business, allowing:

- **Increase enterprise valuation** due additional individual product and business valuations
- Personnel recruitment focused on individual products
- **Funding flexibility** – public, private, debt, licensing, etc.
- **Harvesting flexibility** – sale, licensing, or operations
- Acquisitions into product pipeline are simple and balance sheet accretive

AngioSoma, Inc.
Corporate Structure

- OTCQB quotation ('SOAN') on OTCMarkets.com
  - SEC Periodic Reporting
  - Filings are current
- Common Stock shares
  - 480.0 M authorized
  - 2.7 M float / 32.0 M outstanding
- Preferred Stock shares
  - 20.0 M authorized
  - Series A 10.0 M outstanding (dividend paying)
  - Series B 1.0 M outstanding (voting rights)

AngioSoma, Inc.
Assets

- Subsidiaries
  - AngioSoma Research, Inc. (Texas)
    - Liprostin™ patent & provisional delivery patents
  - First Titan Energy LLC (Nevada)
    - Oil & gas assets in Texas with a planned harvest event to focus on biotechnology
- Other owned assets in product pipeline
  - Patents, provisional patents, expired patents (research & know how), trademarks, etc.

AngioSoma Research, Inc. Liprostin™ Description

Liprostin™ is a novel, multilamellar, freeze-dried liposome formulation containing Prostaglandin E-1 (PGE-1) that has been shown to be stable and prolong the half life of PGE-1 when administered intravenously.

Liprostin™ Highlights

- Patented pharmaceutical
- Phase I & II successful treatment for 100+ patients

  Over $9 M spent so far on trials
- Phase III clinical trials, ready to start...

  budget of $3M and 30 months to approval
- Market of $3.0+ billion annually in North America alone
- Multiple future disease indications for treatment

  painful diabetic neuropathy, unhealing diabetic sores, coronary artery disease, gangrenous conditions facing life and death of amputations, chronic liver disease, and others

Liprostin™ Competitors

- Prostavasin by Schwarz Pharma
  - Approved in Europe, but failed in U.S.
- REOPRO by Eli Lilly
  - Approved worldwide except Japan
- Remodulin by United Therapeutics
  - Approved (PAH)
  - Phase III (PVD)
  - Phase I (CLI)
- Alfimeprase by Nuvelo
  - Phase II (PAOD)

Liprostin™
Prostaglandin E-1 (PGE-1)

- PGE-1 therapeutic activities

  vasodilator, anti-inflammatory, anti-thrombotic, platelet inhibitor, blocks smooth muscle cell migration, stimulates endothelial cell growth, and accelerates wound healing

- PGE-1 approved therapies (Alprostadil, Misoprostol, Prostavasin, Muse)
  - Europe and Asia
    - Fontaine Stages III to IV in arterial occlusive disease of lower limbs (1984)
    - Raynaud's phenomenon
    - Buerger's disease
  - United States
    - Ductus arteriosis of Botalli in neonates (1983)
    - Erectile dysfunction

Liprostin™
PGE-1 In-Vitro Release

Vials of Liprostin were reconstituted with WFI and an in-vitro release study was conducted over a twenty-four hour period, using a VanKel dissolution system. The graphs below represent the concentration of PGE-1 released from the liposomes.





Liprostin™ Phase II Protocol

- Phase II EV 2003-01 Trial for PAOD
  - December 2003 through July 2004 (completed)
  - For Peripheral Arterial Occlusive Disease ('PAOD')
  - 80 patient, multi-site study
  - Protocol submitted under FDA Approved IND 61,026
- Location: Russia and Mexico
- Dose range: 0.1-2.5ug/kg/hr for six treatments
- Duration: Three months
- Primary Endpoints
  - Changes in mean walking distance and pain free walking distance
- Benefits
  - Reduced healthcare costs, improved quality of life

Liprostin™
Phase II Results









Liprostin™
Phase II Results





Liprostin™ Phase II Results

- Seventy three patients completed all ten visits during a three month trial
- 10 visits over 12 weeks
- Baseline determined visits 1-2; Liprostin administered weekly on visits 3-8; follow-up visits 9-10 during third month.
- The average MWD increased 112% over baseline, from 224 meters to 476 meters.
- The average PFMWD increased 189% from 74 meters to 214 meters.
- The average TcPO2 (subset of twenty-three patients at the Georgia site) increased 35% from an O2 pressure of 31 to 42.

Liprostin™ Phase II Conclusions

- Dose range of 0.1-2.5ug/kg/hr established
- Good safety profile confirmed by low incidence of Adverse Events
- Dramatic increase in walking distance and reduction in pain (as indicated by treadmill results) occurs after only six treatments of Liprostin™
- Patient response to PADWIQ questionnaire reveals day to day improvement in quality of life as indicated by 88% increase in overall walking distance and 33% increase in average walking speed
- Increased TcPO2 pressure in extremities indicates improved healing capacity for leg ulcers
- Improvement continues during one month post-treatment follow-up

AngioSoma, Inc.
Contacts

- Alexanderia Blankenship (CEO)
  - Blankenship@angiosoma.com
- David P. "Doc" Summers, PhD. (Chairman Emeritus)
  - Summers@angiosoma.com
- Robert L. Sonfield, Jr. esq (corporate counsel)
  - Robert@sonfield.com

Forward Looking Statements

This investor presentation contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, and other factors that may cause the actual results, performance or achievements of AngioSoma, Inc. to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success is no guarantee of future success. This investor presentation speaks as of the date below and AngioSoma, Inc. assumes no responsibility to update the information included herein for events occurring after the date below.